Research programme: alpha-7 nicotinic acetylcholine receptor modulators - Alpharmagen

Drug Profile

Research programme: alpha-7 nicotinic acetylcholine receptor modulators - Alpharmagen

Latest Information Update: 15 Jan 2015

Price : $50

At a glance

  • Originator Alpharmagen
  • Class
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists; Alpha7 nicotinic acetylcholine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cognition disorders

Most Recent Events

  • 15 Jan 2015 Preclinical trials in Cognition disorders in USA (unspecified route)
  • 14 Jun 2013 Early research in Cognition disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top